Linkage Infrastructure, Equipment And Facilities - Grant ID: LE240100068
Funder
Australian Research Council
Funding Amount
$931,950.00
Summary
Australian Advanced Metabolic Signal Discovery, and Imaging Platform. This proposal aims to establish an Australian Advanced Metabolic Signal Discovery and Imaging platform. The platform consists of an ultra-high resolution gas chromatography mass spectrometer and an imaging mass spectrometry upgrade for a second existing high resolution mass spectrometer. The facility will break barriers currently limiting discovery and localisation of metabolic changes during plant and animal development under ....Australian Advanced Metabolic Signal Discovery, and Imaging Platform. This proposal aims to establish an Australian Advanced Metabolic Signal Discovery and Imaging platform. The platform consists of an ultra-high resolution gas chromatography mass spectrometer and an imaging mass spectrometry upgrade for a second existing high resolution mass spectrometer. The facility will break barriers currently limiting discovery and localisation of metabolic changes during plant and animal development under environmental stress; integral chemical signals exchanged in host-microbe interactions; and volatile signatures linked to ecosystem health and developmental anomalies in animals. Results will inform innovative strategies to enhance biological adaptation, climate resilience and plant, animal, and ecosystem health.Read moreRead less
Chemo-prevention of tropical canine parasitoses and vector-borne diseases. This project will determine the prevalence and diversity of established, emerging and novel canine vector-borne agents and endoparasites in a tropical setting by using conventional and next generation molecular diagnostic tools. It will fill an important gap by providing independently-verified evidence on how well canine anti-parasitic products marketed in Australia and Asia by Bayer Animal Health, perform in high-infecti ....Chemo-prevention of tropical canine parasitoses and vector-borne diseases. This project will determine the prevalence and diversity of established, emerging and novel canine vector-borne agents and endoparasites in a tropical setting by using conventional and next generation molecular diagnostic tools. It will fill an important gap by providing independently-verified evidence on how well canine anti-parasitic products marketed in Australia and Asia by Bayer Animal Health, perform in high-infection pressure settings, as a chemo-preventative for these disease agents. Tropical regions spanning northern Australia and Southern Asia are highly conducive to a plethora of canine vector-borne and parasitic pathogens that cause significant morbidity and mortality in dogs. Many of these agents also pose a risk to public health. The outcomes will be directly translated to best-practice guidelines for the advancement of companion animal (and indirectly human) health and welfare.Read moreRead less
Understanding heat shock protein complex vaccines. This project aims to understand the mechanism of action and formulation requirements of a novel vaccine technology that utilises heat shock protein complexes. By understanding how this technology works, future vaccines can be improved to induce the immune response required to target specific pathogens, as well as give assurance regarding its safety.
Public health approach to child abuse and neglect: antecedents, outcomes and international comparisons of trends. Child maltreatment is a significant public health issue. Findings will identify characteristics of at-risk children, families and communities; mental health and juvenile justice outcomes. Findings will be used to develop policy recommendations for intervention and prevention strategies to reduce vulnerability and improve monitoring of maltreatment.
The role of a novel protein, interferon epsilon, in reproductive tract immunity. This project aims to develop a world-first description of a new protein that has a protective role against female reproductive tract infections. This unique protein, called interferon epsilon, was discovered in our laboratory. This project will facilitate development of new therapeutic approaches of benefit in diseases such as Chlamydia and Herpes Simplex Virus.